Evolution of transdermal oxybutynin in the treatment of overactive bladder

International Journal of Clinical Practice

Volumn 62, Issue 1, 2008, Pages 167-170

  Sahai, A ^a,c   Mallina, R ^b   Dowson, C ^a   Larner, T ^a   Khan, M S ^b  

^a UK   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; DRUG METABOLITE; N DESETHYLOXYBUTYNIN; OXYBUTYNIN; PLACEBO; TOLTERODINE; TRIACETIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CLINICAL TRIAL; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG TOLERABILITY; HUMAN; MEDLINE; MIXED INCONTINENCE; OVERACTIVE BLADDER; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM; UNITED STATES; URINE INCONTINENCE; URODYNAMICS; XEROSTOMIA;

ADMINISTRATION, CUTANEOUS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; HUMANS; MANDELIC ACIDS; MUSCARINIC ANTAGONISTS; URINARY BLADDER, OVERACTIVE;

EID: 37349000215     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01623.x     Document Type: Review

References (16)

1. Abrams P, Cardozo L, Fall M et al. Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 167 78.
2. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006 50 : 1306 14.
3. Reeves P, Irwin D, Kelleher C et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006 50 : 1050 7.
4. Chess-Williams R, Chapple CR, Yamanishi T, Yasuda K, Sellers DJ. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 2001 21 : 243 8.
5. Zobrist RH, Schmid B, Feick A, Quan D, Sanders SW. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm Res 2001 18 : 1029 34.
6. Zobrist RH, Quan D, Thomas HM, Stanworth S, Sanders SW. Pharmacokinetics and metabolism of transdermal oxybutinin: in vitro and in vivo performance of a novel drug delivery system. Pharm Res 2003 20 : 103 9.
7. Appell RA, Chancellor MB, Zobrist RH, Thomas H, Sanders SW. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc 2003 78 : 696 702.
8. Davila GW, Daugherty CA, Sanders SW, Transdermal Oxybutynin Study Group. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence. J Urol 2001 166 : 140 5.
9. Dmochowski RR, Davila GW, Zinner NR et al. For The Transdermal Oxybutynin Study Group. Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence. J Urol 2002 168 : 580 6.
10. Dmochowski RR, Sand PK, Zinner NR, Gittelman MC, Davila GW, Sanders SW Transdermal Oxybutynin Study Group. Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology 2003 62 : 237 42.
11. Dmochowski RR, Nitti V, Staskin D, Luber K, Appell RA, Davila GW. Transdermal oxybutynin in the treatment of adults with overactive bladder: combined results of two randomized clinical trials. World J Urol 2005 23 : 263 70.
12. Sand P, Zinner N, Newman D et al. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int 2007 99 : 836 44.
13. Sand PK, Goldberg RP, Dmochowski RR, McIlwain M, Dahl NV. The impact of the overactive bladder syndrome on sexual function: a preliminary report from the Multicenter Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin trial. Am J Obstet Gynecol 2006 195 : 1730 5.
14. Dull P. Transdermal oxybutynin (oxytrol) for urinary incontinence. Am Fam Physician 2004 70 : 2351 2.
15. Urinary incontinence: the management of urinary incontinence in women. NICE Guidelines. http://guidance.nice.org.uk/CG40 (accessed September 2007).
16. MyRxHealth.com. http://www.myrxhealth.com (accessed February 2007).